Paradigm chief Paul Rennie on IPPS blockbuster potential, 50% phase three milestone

Welcome to the latest HotCopper Capital Compass, where we’ve this week spoken to Paradigm Biopharma (ASX:PAR) founder and managing director Paul Rennie about Paradigm arriving at its “pivotal” phase three trial, which will be examining outcomes of its flagship drug Zilosul on osteoarthritis.

Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.

Disclaimer: This content has been prepared as part of an ongoing partnership with Paradigm Biopharma Ltd and is intended for informational purposes only.

“Phase three is very much in the pharmaceutical industry like the grand final is to the football codes. It is the big stage in the development of a company or a sporting team,” Mr Rennie told The Market Link.

He added: “We have, from the outset, 10 years ago, developed a plan that put together all the necessary information that means when you get the grand final and get all your data, you can sit down with the agency – for us, the U.S. FDA – and now we’re preparing to submit a dossier there.”

For a full overview on PAR, you can watch the interview in the browser above.

Join the discussion. See what HotCopper users are saying about Paradigm Biopharma Ltd and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.